Developmental toxicities, sex disparities, and temporal kinetics of tyrosine kinase inhibitors in paediatric leukaemia: A real-world pharmacovigilance study
While tyrosine kinase inhibitors (TKIs) have significantly advanced paediatric leukaemia management, real-world safety signals and reported event timing in paediatric populations remain less defined compared to adults. We conducted a pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) to evaluate four TKIs (imatinib, dasatinib, nilotinib, and ponatinib). Standardised drug name mapping and deduplication protocols were applied. Disproportionality analyses (calculating reporting odds ratios [RORs] with 95% confidence intervals [CIs]) were performed to detect adverse drug event (ADE) signals. Weibull shape parameter analyses were used to evaluate the temporal distribution of reported time-to-onset among cases with available dates. Disproportionality analysis identified distinct ADE reporting signals in paediatric cases. Dasatinib showed a strong disproportionality signal for chylothorax (ROR, 315.78; 95% CI, 142.65-699.04; n = 7 events). Imatinib was associated with signals for physical development interference, including pubertal failure (ROR, 399.30; 95% CI, 103.24-1544.37; n = 7 events). Sex-stratified analyses did not demonstrate statistically significant differences in growth impairment between male and female patients. Time-to-onset distributions indicated that recorded onset dates were concentrated early in therapy, with 41.25% of imatinib-associated and 26.13% of dasatinib-associated ADE reports occurring within the first 30 days of treatment. Spontaneous reporting data reveal specific disproportionality signals and early reporting patterns for TKIs in paediatric patients. Although these findings cannot infer causality, true incidence, or underlying biological mechanisms due to FAERS database limitations, they generate meaningful safety hypotheses that support proactive clinical surveillance upon TKI initiation.
Authors
- Fangyu Song
- Mo Sun (ORCID: https://orcid.org/0009-0000-7467-6490)
- Tong Chen (ORCID: https://orcid.org/0000-0001-5953-8313)
- Jinhao He
- Jiaqi Sun
- Jiali Xue
- Lanlan Yan
- Zijun Yan
- Chenning Zhang
Institutions
- Hubei University of Medicine (CN)
- Georgia Institute of Technology (US)
- Chengdu Medical College (CN)
- Kunming Medical University (CN)
- Taihe Hospital (CN)
- Panzhihua Central Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1186/s12885-026-17303-5
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province